# Pembrolizumab

KEYNOTE-054

Pembrolizumab KEYNOTE-054

## PRELIMINARY SCORE

**CURATIVE**

DFS

**NON-CURATIVE**

## ADJUSTMENTS

**Quality of life**

Not qualified for an ESMO-MCBS credit

**Serious and disabling adverse effects**

**Other adjustments**

**Pembrolizumab KEYNOTE-054**

## SCORE

**CURATIVE**

A

Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Skin Cancers
Therapeutic Indication: EMA: Pembrolizumab for adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma and who have undergone complete resection.. FDA: Pembrolizumab for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) following complete resection.
Experimental Arm: Pembrolizumab
Control Arm: Placebo